MedTrace Logo

Spinraza in Adult Spinal Muscular Atrophy

NCT03709784 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2024-11-20

No results posted yet for this study

Summary

This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

Conditions

Interventions

DRUG

Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care

This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

OTHER

One time survey

One time survey

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Craig Zaidman, MD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2024-12-31
Completion
2025-01-01
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709784 on ClinicalTrials.gov